At the heart of the showdown is a deep split among federal circuit courts over whether federal law overrides state failure-to-warn claims in Roundup personal-injury suits
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
LANXESS Biosecurity Solutions aims to deliver “advanced disinfection and hygiene solutions to support Indian farmers in maintaining healthier and safer farm environments
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
The FDA has classified recent submissions as a major amendment pushing the approval to its NDA for TransCon CNP back three months to February 28, 2026
This distinction is testament to LHWRF's dedication to excellence, transparency, and impact in the realm of social responsibility
GV20 received an upfront payment and is eligible for additional milestone payments
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Renalyx will continue operating as an independent unit within the group
Subscribe To Our Newsletter & Stay Updated
